Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

by | Mar 2, 2026 | Clinical Trials | 0 comments

​ Conditions: Phase II; Sacituzumab; Tirumotecan; SMARCB1-deficient Renal Medullary Carcinoma

Interventions: Drug: Sacituzumab tirumotecan

Sponsors: M.D. Anderson Cancer Center; Merck Sharp & Dohme LLC

Not yet recruiting Conditions: Phase II; Sacituzumab; Tirumotecan; SMARCB1-deficient Renal Medullary Carcinoma
Interventions: Drug: Sacituzumab tirumotecan
Sponsors: M.D. Anderson Cancer Center; Merck Sharp & Dohme LLC
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *